| 27.49 -0.01 (-0.04%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.13 | 1-year : | 37.52 |
| Resists | First : | 27.51 | Second : | 32.13 |
| Pivot price | 27.38  |
|||
| Supports | First : | 27.19 | Second : | 27 |
| MAs | MA(5) : | 27.48 | MA(20) : | 27.3 |
| MA(100) : | 25.4 |
MA(250) : | 18.26 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 96 | D(3) : | 96 |
| RSI | RSI(14): 72 | |||
| 52-week | High : | 27.51 | Low : | 6.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SILK ] has closed below upper band by 33.5%. Bollinger Bands are 73% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.55 - 27.69 | 27.69 - 27.8 |
| Low: | 27.11 - 27.29 | 27.29 - 27.45 |
| Close: | 27.23 - 27.51 | 27.51 - 27.74 |
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Mon, 22 Sep 2025
Ceribell appoints former Silk Road Medical CEO to board of directors - Investing.com
Mon, 22 Sep 2025
Former Silk Road Medical CEO joins CeriBell’s board - MassDevice
Wed, 06 Aug 2025
ONWARD Strengthens Board with Ex-Silk Road Medical CFO Who Led $3.7B Boston Scientific Deal - Stock Titan
Wed, 12 Mar 2025
Should You Buy Silk Road Medical Inc (SILK) Stock After it Is Down 16.04% in a Week? - Investorsobserver
Mon, 03 Mar 2025
Endologix brings on former Silk Road Medical exec as CCO - MassDevice
Mon, 28 Oct 2024
Boston Scientific to close Silk Road Medical headquarters, lay off 138 people - MedTech Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 97.4 (%) |
| Shares Short | 3,150 (K) |
| Shares Short P.Month | 2,570 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.8 |
| Profit Margin | -29.6 % |
| Operating Margin | -33.6 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -36.5 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.71 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -18.96 |
| PEG Ratio | -11.8 |
| Price to Book value | 7.21 |
| Price to Sales | 5.83 |
| Price to Cash Flow | -32.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|